Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


Articles published in Ann Hematol

Retrieve available abstracts of 145 articles:
HTML format
Text format



Single Articles


    November 2018
  1. BODDU P, Chihara D, Masarova L, Pemmaraju N, et al
    The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.
    Ann Hematol. 2018;97:2071-2080.
    PubMed     Text format     Abstract available


    October 2018
  2. KHALIL MMI, Messner HA, Lipton JH, Kim DD, et al
    Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
    Ann Hematol. 2018;97:1975-1985.
    PubMed     Text format     Abstract available


  3. EGLE A, Steurer M, Melchardt T, Weiss L, et al
    Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
    Ann Hematol. 2018;97:1825-1839.
    PubMed     Text format     Abstract available


  4. FORBRIGGER Z, Kuhle S, Brown MM, Moorehead PC, et al
    The association of venous thromboembolism with survival in pediatric cancer patients: a population-based cohort study.
    Ann Hematol. 2018;97:1903-1908.
    PubMed     Text format     Abstract available


    September 2018
  5. URESHINO H, Kusaba K, Kidoguchi K, Sano H, et al
    Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
    Ann Hematol. 2018 Sep 27. pii: 10.1007/s00277-018-3502.
    PubMed     Text format     Abstract available


  6. JUNG SH, Lee SR, Yang DH, Lee S, et al
    Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party.
    Ann Hematol. 2018 Sep 26. pii: 10.1007/s00277-018-3495.
    PubMed     Text format     Abstract available


  7. STEIN AS, Schiller G, Benjamin R, Jia C, et al
    Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors.
    Ann Hematol. 2018 Sep 20. pii: 10.1007/s00277-018-3497.
    PubMed     Text format     Abstract available


  8. VAN DE LOUW A, Lewis AM, Yang Z
    Autopsy findings in patients with acute myeloid leukemia and non-Hodgkin lymphoma in the modern era: a focus on lung pathology and acute respiratory failure.
    Ann Hematol. 2018 Sep 14. pii: 10.1007/s00277-018-3494.
    PubMed     Text format     Abstract available


  9. ELBAEK MV, Sorensen AL, Hasselbalch HC
    Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?
    Ann Hematol. 2018 Sep 4. pii: 10.1007/s00277-018-3489.
    PubMed     Text format     Abstract available


  10. TIMMERS NKLM, de Maar JS, van Kruijsdijk RCM, Klein SK, et al
    Central nervous system localisation of chronic lymphocytic leukaemia, description of two very distinct cases and a review of the literature.
    Ann Hematol. 2018;97:1627-1632.
    PubMed     Text format     Abstract available


  11. HATTA Y, Mizuta S, Matsuo K, Ohtake S, et al
    Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
    Ann Hematol. 2018;97:1535-1545.
    PubMed     Text format     Abstract available


    August 2018
  12. WANG H, Li Y, Lv N, Li Y, et al
    Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
    Ann Hematol. 2018 Aug 6. pii: 10.1007/s00277-018-3464.
    PubMed     Text format     Abstract available


  13. SCHULER E, Zadrozny N, Blum S, Schroeder T, et al
    Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.
    Ann Hematol. 2018 Aug 4. pii: 10.1007/s00277-018-3466.
    PubMed     Text format     Abstract available


  14. XIAO H, Li L, Pang Y, Wu Y, et al
    Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia.
    Ann Hematol. 2018 Aug 4. pii: 10.1007/s00277-018-3453.
    PubMed     Text format     Abstract available


  15. MONTORO J, Gallur L, Merchan B, Molero A, et al
    Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
    Ann Hematol. 2018;97:1349-1356.
    PubMed     Text format     Abstract available


  16. DE ALVARENGA EC, Silva WN, Vasconcellos R, Paredes-Gamero EJ, et al
    Promyelocytic leukemia protein in mesenchymal stem cells is essential for leukemia progression.
    Ann Hematol. 2018 Aug 1. pii: 10.1007/s00277-018-3463.
    PubMed     Text format     Abstract available


    July 2018
  17. SCHNEIDAWIND C, Hagmaier V, Faul C, Kanz L, et al
    Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia.
    Ann Hematol. 2018 Jul 31. pii: 10.1007/s00277-018-3454.
    PubMed     Text format     Abstract available


  18. GU B, Zhang X, Chen G, Wu X, et al
    Efficacy of haploidentical hematopoietic stem cell transplantation compared to HLA-matched transplantation for primary refractory acute myeloid leukemia.
    Ann Hematol. 2018 Jul 23. pii: 10.1007/s00277-018-3428.
    PubMed     Text format     Abstract available


  19. PARK E, Jue MS
    Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review.
    Ann Hematol. 2018 Jul 21. pii: 10.1007/s00277-018-3444.
    PubMed     Text format    


  20. BURNS TF, Loo EY, Bengtson EM, Bao L, et al
    Cytogenetically cryptic insertion of PML segment into RARA on chromosome 17q resulting PML-RARA fusion in acute promyelocytic leukemia.
    Ann Hematol. 2018 Jul 20. pii: 10.1007/s00277-018-3399.
    PubMed     Text format    


  21. ZHANG G, Zhang L, Yang X, Zhang X, et al
    High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2018 Jul 18. pii: 10.1007/s00277-018-3440.
    PubMed     Text format    


  22. ZAPPASODI P, Marbello L, Borlenghi E, Fumagalli M, et al
    Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
    Ann Hematol. 2018 Jul 15. pii: 10.1007/s00277-018-3424.
    PubMed     Text format     Abstract available


  23. LIN XJ, Dai HP, Wang AJ, Chen F, et al
    Effects of preemptive interferon-alpha monotherapy in acute leukemia patients with relapse tendency after allogeneic hematopoietic stem cell transplantation: a case-control study.
    Ann Hematol. 2018 Jul 11. pii: 10.1007/s00277-018-3429.
    PubMed     Text format     Abstract available


  24. DUGGE R, Kreipe H, Rosenwald A, Lehmann U, et al
    Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis.
    Ann Hematol. 2018 Jul 7. pii: 10.1007/s00277-018-3434.
    PubMed     Text format    


  25. KONUMA T, Mizuno S, Kondo T, Yamaguchi H, et al
    Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).
    Ann Hematol. 2018 Jul 6. pii: 10.1007/s00277-018-3419.
    PubMed     Text format     Abstract available


  26. SUEDA S, Nakayama S, Adachi T, Ohashi Y, et al
    Cytotoxic T-lymphocyte-associated antigen 4-positive aggressive adult T cell leukemia/lymphoma.
    Ann Hematol. 2018 Jul 6. pii: 10.1007/s00277-018-3426.
    PubMed     Text format    


  27. MEGIAS-VERICAT JE, Martinez-Cuadron D, Sanz MA, Montesinos P, et al
    Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
    Ann Hematol. 2018;97:1115-1153.
    PubMed     Text format     Abstract available


  28. VANDER MEEREN S, Heyrman B, Renmans W, Bakkus M, et al
    Lymphoma-like monoclonal B cell lymphocytosis in a patient population: biology, natural evolution, and differences from CLL-like clones.
    Ann Hematol. 2018;97:1219-1227.
    PubMed     Text format     Abstract available


    June 2018
  29. KRISTON C, Plander M, Mark A, Sebestyen A, et al
    In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment.
    Ann Hematol. 2018 Jun 28. pii: 10.1007/s00277-018-3410.
    PubMed     Text format     Abstract available


  30. OSORIO S, Escudero-Vilaplana V, Gomez-Centurion I, Perez-Lopez R, et al
    Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
    Ann Hematol. 2018 Jun 28. pii: 10.1007/s00277-018-3413.
    PubMed     Text format     Abstract available


  31. KUBOTA Y, Kamachi K, Wakayama K, Kitamura H, et al
    Acute myeloid leukemia with t(19;21)(q13;q22) and marked eosinophilia.
    Ann Hematol. 2018 Jun 27. pii: 10.1007/s00277-018-3408.
    PubMed     Text format    


  32. CICCONI L, Breccia M, Franceschini L, Latagliata R, et al
    Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
    Ann Hematol. 2018 Jun 27. pii: 10.1007/s00277-018-3400.
    PubMed     Text format     Abstract available


  33. FUJIOKA I, Takaku T, Iriyama N, Tokuhira M, et al
    Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.
    Ann Hematol. 2018 Jun 26. pii: 10.1007/s00277-018-3412.
    PubMed     Text format     Abstract available


  34. STRUGOV V, Stadnik E, Virts Y, Andreeva T, et al
    Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia.
    Ann Hematol. 2018 Jun 26. pii: 10.1007/s00277-018-3409.
    PubMed     Text format     Abstract available


  35. ZHU Y, Gao Q, Du J, Hu J, et al
    Effects of post-remission chemotherapy before allo-HSCT for acute myeloid leukemia during first complete remission: a meta-analysis.
    Ann Hematol. 2018 Jun 26. pii: 10.1007/s00277-018-3414.
    PubMed     Text format     Abstract available


  36. FEDERMANN B, Mueller MR, Steinhilber J, Horger MS, et al
    Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales.
    Ann Hematol. 2018 Jun 12. pii: 10.1007/s00277-018-3390.
    PubMed     Text format     Abstract available


  37. MAURILLO L, Buccisano F, Spagnoli A, Voso MT, et al
    Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
    Ann Hematol. 2018 Jun 10. pii: 10.1007/s00277-018-3374.
    PubMed     Text format     Abstract available


  38. LIU H, Wang SA, Schlette EJ, Xu J, et al
    Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1.
    Ann Hematol. 2018 Jun 5. pii: 10.1007/s00277-018-3389.
    PubMed     Text format     Abstract available


  39. SAKELLARI I, Gavriilaki E, Chatziioannou K, Papathanasiou M, et al
    Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study.
    Ann Hematol. 2018 Jun 5. pii: 10.1007/s00277-018-3383.
    PubMed     Text format     Abstract available


  40. SAHIN U, Dalva K, Gungor F, Ustun C, et al
    Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Ann Hematol. 2018;97:1027-1039.
    PubMed     Text format     Abstract available


  41. ZERKALENKOVA E, Panfyorova A, Kazakova A, Baryshev P, et al
    Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG.
    Ann Hematol. 2018;97:977-988.
    PubMed     Text format     Abstract available


  42. ZHAO X, Wang Z, Ruan G, Liu Y, et al
    Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
    Ann Hematol. 2018;97:967-975.
    PubMed     Text format     Abstract available


  43. STRENGER V, Merth G, Lackner H, Aberle SW, et al
    Malignancy and chemotherapy induced haemophagocytic lymphohistiocytosis in children and adolescents-a single centre experience of 20 years.
    Ann Hematol. 2018;97:989-998.
    PubMed     Text format     Abstract available


    May 2018
  44. IWASHIGE A, Hirosawa M, Tsukada J
    Hairy cell leukemia presenting with progressive pericarditis and pleuritis.
    Ann Hematol. 2018 May 30. pii: 10.1007/s00277-018-3378.
    PubMed     Text format    


  45. MOLICA M, Scalzulli E, Colafigli G, Fegatelli DA, et al
    Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
    Ann Hematol. 2018 May 27. pii: 10.1007/s00277-018-3375.
    PubMed     Text format     Abstract available


  46. BILL M, Grimm J, Jentzsch M, Kloss L, et al
    Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Ann Hematol. 2018 May 22. pii: 10.1007/s00277-018-3373.
    PubMed     Text format     Abstract available


  47. ALLAIN EP, Venzl K, Caron P, Turcotte V, et al
    Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients.
    Ann Hematol. 2018 May 21. pii: 10.1007/s00277-018-3356.
    PubMed     Text format     Abstract available


  48. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis.
    Ann Hematol. 2018 May 8. pii: 10.1007/s00277-018-3350.
    PubMed     Text format    


  49. MIAO Y, Miao Y, Shi K, Sun Q, et al
    A higher percentage of cells with 13q deletion predicts worse outcome in Chinese patients with chronic lymphocytic leukemia carrying isolated 13q deletion.
    Ann Hematol. 2018 May 7. pii: 10.1007/s00277-018-3359.
    PubMed     Text format     Abstract available


  50. MARHALL A, Heidel F, Fischer T, Ronnstrand L, et al
    Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Ann Hematol. 2018;97:773-780.
    PubMed     Text format     Abstract available


  51. VIGNOLI A, Marchetti M, Falanga A
    Acute promyelocytic leukemia cell adhesion to vascular endothelium is reduced by heparins.
    Ann Hematol. 2018 May 1. pii: 10.1007/s00277-018-3343.
    PubMed     Text format     Abstract available


    April 2018
  52. HONG Y, Zhao X, Qin Y, Zhou S, et al
    The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2018 Apr 28. pii: 10.1007/s00277-018-3338.
    PubMed     Text format     Abstract available


  53. COLTOFF A, Houldsworth J, Keyzner A, Renteria AS, et al
    Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Ann Hematol. 2018 Apr 27. pii: 10.1007/s00277-018-3330.
    PubMed     Text format     Abstract available


  54. ZHANG J, Shi J, Zhang G, Zhang X, et al
    BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2018 Apr 25. pii: 10.1007/s00277-018-3331.
    PubMed     Text format     Abstract available


  55. ZHANG X, Li B, Yu J, Dahlstrom J, et al
    Correction to: MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
    Ann Hematol. 2018 Apr 25. pii: 10.1007/s00277-018-3340.
    PubMed     Text format     Abstract available


  56. BRECCIA M, Abruzzese E, Castagnetti F, Bonifacio M, et al
    Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.
    Ann Hematol. 2018 Apr 19. pii: 10.1007/s00277-018-3337.
    PubMed     Text format     Abstract available


  57. WANG X, Zhang L, Zhao F, Xu R, et al
    Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia.
    Ann Hematol. 2018 Apr 13. pii: 10.1007/s00277-018-3315.
    PubMed     Text format     Abstract available


  58. LO WJ, Lin CL, Chang YC, Bai LY, et al
    Total body irradiation tremendously impair the proliferation, differentiation and chromosomal integrity of bone marrow-derived mesenchymal stromal stem cells.
    Ann Hematol. 2018;97:697-707.
    PubMed     Text format     Abstract available


  59. SCAPPATICCI GB, Marini BL, Nachar VR, Uebel JR, et al
    Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
    Ann Hematol. 2018;97:573-584.
    PubMed     Text format     Abstract available


    March 2018
  60. SUZUKI Y, Honda A, Nakazaki K, Mizuno H, et al
    Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy.
    Ann Hematol. 2018 Mar 26. pii: 10.1007/s00277-018-3300.
    PubMed     Text format    


  61. SAINI NY, Bathini V
    Large granular lymphocytic leukemia-associated peripheral neuropathy.
    Ann Hematol. 2018 Mar 22. pii: 10.1007/s00277-018-3310.
    PubMed     Text format    


  62. KHAN M, Muzzafar T, Kantarjian H, Badar I, et al
    Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
    Ann Hematol. 2018 Mar 20. pii: 10.1007/s00277-018-3289.
    PubMed     Text format     Abstract available


  63. PIATOPOULOU D, Avgeris M, Drakaki I, Marmarinos A, et al
    Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Ann Hematol. 2018 Mar 20. pii: 10.1007/s00277-018-3292.
    PubMed     Text format     Abstract available


  64. KIM DW, Saussele S, Williams LA, Mohamed H, et al
    Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.
    Ann Hematol. 2018 Mar 20. pii: 10.1007/s00277-018-3295.
    PubMed     Text format     Abstract available


  65. KHAN M, Siddiqi R, Naqvi K
    An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL).
    Ann Hematol. 2018 Mar 15. pii: 10.1007/s00277-018-3297.
    PubMed     Text format     Abstract available


  66. HA J, Kim B, Hahn S, Lee ST, et al
    A patient with B-cell acute lymphoblastic leukemia with PAX5-ETV6 rearrangement with dic(9;12)(p13;p13) identified by chromosomal microarray.
    Ann Hematol. 2018 Mar 8. pii: 10.1007/s00277-018-3291.
    PubMed     Text format    


  67. PARK S, Choi H, Kim HJ, Ahn JS, et al
    Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients.
    Ann Hematol. 2018 Mar 2. pii: 10.1007/s00277-018-3260.
    PubMed     Text format     Abstract available


  68. HIDALGO LOPEZ JE, Carballo-Zarate A, Verstovsek S, Wang SA, et al
    Bone marrow findings in blast phase of polycythemia vera.
    Ann Hematol. 2018;97:425-434.
    PubMed     Text format     Abstract available


  69. HARADA K, Doki N, Miyazaki Y, Wakita A, et al
    Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200.
    Ann Hematol. 2018 Mar 1. pii: 10.1007/s00277-018-3281.
    PubMed     Text format    


    February 2018
  70. MARTINEZ-CUADRON D, Boluda B, Martinez P, Bergua J, et al
    Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2018 Feb 23. pii: 10.1007/s00277-018-3277.
    PubMed     Text format     Abstract available


  71. BRECCIA M, Palandri F, Luciano L, Benevolo G, et al
    Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment.
    Ann Hematol. 2018 Feb 22. pii: 10.1007/s00277-018-3258.
    PubMed     Text format     Abstract available


  72. SHIMOMURA Y, Hara M, Katoh D, Hashimoto H, et al
    Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Ann Hematol. 2018 Feb 17. pii: 10.1007/s00277-018-3278.
    PubMed     Text format     Abstract available


  73. ZHAO HY, Song Y, Cao XN, Qin YZ, et al
    Leukemia-propagating cells demonstrate distinctive gene expression profiles compared with other cell fractions from patients with de novo Philadelphia chromosome-positive ALL.
    Ann Hematol. 2018 Feb 10. pii: 10.1007/s00277-018-3253.
    PubMed     Text format     Abstract available


  74. NAKAYAMA S, Matsuda M, Adachi T, Sueda S, et al
    Adult T cell leukemia/lymphoma with different pathological features in each tumor site.
    Ann Hematol. 2018 Feb 9. pii: 10.1007/s00277-018-3272.
    PubMed     Text format    


  75. SUZUKI Y, Koya J, Ebisawa K, Abe H, et al
    Sequential development of monoclonal B cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia.
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3248.
    PubMed     Text format    


  76. WEI G, Hu Y, Pu C, Yu J, et al
    CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3246.
    PubMed     Text format     Abstract available


  77. DI BLASI R, Cattaneo C, Lewis RE, Tumbarello M, et al
    Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL).
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3252.
    PubMed     Text format     Abstract available


  78. TACHIKI L, Dong ZM, Burwick N
    Atypical chronic lymphocytic leukemia presenting with massive IgM paraprotein.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3261.
    PubMed     Text format    


  79. MORITA K, Koya J, Toya T, Nakamura F, et al
    Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3263.
    PubMed     Text format    


  80. FUJIMI A, Nagamachi Y, Yamauchi N
    Extramedullary involvement of the stomach presenting as multiple white elevations in the initial diagnosis of chronic myeloid leukemia treated with dasatinib.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3268.
    PubMed     Text format    


  81. MARTINEZ-CUADRON D, Boluda B, Martinez P, Bergua J, et al
    A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2018 Feb 2. pii: 10.1007/s00277-018-3229.
    PubMed     Text format     Abstract available


  82. MELLINGHOFF SC, Panse J, Alakel N, Behre G, et al
    Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Ann Hematol. 2018;97:197-207.
    PubMed     Text format     Abstract available


  83. DUONG VH, Padron E, Al Ali NH, Lancet JE, et al
    The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
    Ann Hematol. 2018;97:247-254.
    PubMed     Text format     Abstract available


  84. SCHROEDER T, Rautenberg C, Kruger W, Platzbecker U, et al
    Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Ann Hematol. 2018;97:335-342.
    PubMed     Text format     Abstract available


  85. MINODA S, Akasaka T, Okanoue Y, Honjo G, et al
    Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization.
    Ann Hematol. 2018 Feb 1. pii: 10.1007/s00277-018-3235.
    PubMed     Text format    


  86. SHAHKARAMI S, Mehrasa R, Younesian S, Yaghmaie M, et al
    Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
    Ann Hematol. 2018 Feb 1. pii: 10.1007/s00277-018-3230.
    PubMed     Text format     Abstract available


    January 2018
  87. SAEED OAM, Longe HO, Zhou J
    T cell large granular lymphocytic leukemia, a rare form of post lung transplant lymphoproliferative disorder.
    Ann Hematol. 2018 Jan 8. pii: 10.1007/s00277-017-3213.
    PubMed     Text format    


  88. BEN LAKHAL R, Ghedira H, Bellaaj H, Ben Youssef Y, et al
    Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ann Hematol. 2018 Jan 6. pii: 10.1007/s00277-017-3224.
    PubMed     Text format     Abstract available


  89. KAMEDA K, Kako S, Hayakawa J, Akahoshi Y, et al
    Safety of avoiding systemic corticosteroid administration for grade II acute graft-versus-host disease limited to the skin.
    Ann Hematol. 2018;97:169-179.
    PubMed     Text format     Abstract available


    December 2017
  90. ZHAO H, Zhao Y, Zhang Y, Hou J, et al
    Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.
    Ann Hematol. 2017 Dec 30. pii: 10.1007/s00277-017-3216.
    PubMed     Text format     Abstract available


  91. SADEGHI N, Li HC
    MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab.
    Ann Hematol. 2017 Dec 28. pii: 10.1007/s00277-017-3219.
    PubMed     Text format    


  92. YANG J, Cai Y, Jiang J, Wan L, et al
    Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia.
    Ann Hematol. 2017 Dec 18. pii: 10.1007/s00277-017-3204.
    PubMed     Text format     Abstract available


  93. HARADA K, Doki N, Hagino T, Miyawaki S, et al
    Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.
    Ann Hematol. 2017 Dec 2. pii: 10.1007/s00277-017-3156.
    PubMed     Text format     Abstract available


    November 2017
  94. HILMI M, Bally C, Burns R, Lorillon G, et al
    Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine.
    Ann Hematol. 2017 Nov 23. pii: 10.1007/s00277-017-3190.
    PubMed     Text format    


  95. HASSANI S, Khaleghian A, Ahmadian S, Alizadeh S, et al
    Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4).
    Ann Hematol. 2017 Nov 20. doi: 10.1007/s00277-017-3163.
    PubMed     Text format     Abstract available


  96. PRATS-MARTIN C, Jimenez-Guerrero P, Morales-Camacho RM, Caballero-Velazquez T, et al
    KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2017 Nov 18. doi: 10.1007/s00277-017-3187.
    PubMed     Text format    


  97. SHAO H, Yang Q, Zhang P, Liu H, et al
    Simultaneous occurrence of two distinct leukemic clones with PML-RARalpha and RUNX1-RUNX1T1 in a case of acute myeloid leukemia.
    Ann Hematol. 2017 Nov 9. doi: 10.1007/s00277-017-3169.
    PubMed     Text format    


  98. LORENZANA N, Avila LF, Alonso S, Colado E, et al
    The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment.
    Ann Hematol. 2017;96:1833-1840.
    PubMed     Text format     Abstract available


    October 2017
  99. NASSEREDDINE S, Lap CJ, Haroun F, Tabbara I, et al
    The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
    Ann Hematol. 2017 Oct 31. doi: 10.1007/s00277-017-3161.
    PubMed     Text format     Abstract available


  100. NAGEL G, Weber D, Fromm E, Erhardt S, et al
    Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).
    Ann Hematol. 2017 Oct 31. doi: 10.1007/s00277-017-3150.
    PubMed     Text format     Abstract available


  101. YANG D, Zhang X, Zhang X, Xu Y, et al
    The progress and current status of immunotherapy in acute myeloid leukemia.
    Ann Hematol. 2017 Oct 28. doi: 10.1007/s00277-017-3148.
    PubMed     Text format     Abstract available


  102. ZHANG X, Li B, Yu J, Dahlstrom J, et al
    MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
    Ann Hematol. 2017 Oct 27. doi: 10.1007/s00277-017-3158.
    PubMed     Text format     Abstract available


  103. KHAN M, Siddiqi R, Thompson PA
    Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.
    Ann Hematol. 2017 Oct 23. doi: 10.1007/s00277-017-3149.
    PubMed     Text format     Abstract available


  104. GUTIERREZ-AGUIRRE CH, Flores-Jimenez JA, Alatorre-Ricardo J, Cantu-Rodriguez OG, et al
    The prognostic significance of serum XCL1 concentration in patients with acute lymphoblastic leukemia: a pilot study.
    Ann Hematol. 2017 Oct 13. doi: 10.1007/s00277-017-3142.
    PubMed     Text format     Abstract available


  105. TERADA K, Yamaguchi H, Ueki T, Usuki K, et al
    Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor.
    Ann Hematol. 2017 Oct 4. doi: 10.1007/s00277-017-3143.
    PubMed     Text format     Abstract available


  106. IURLO A, Galimberti S, Abruzzese E, Annunziata M, et al
    Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
    Ann Hematol. 2017 Oct 2. doi: 10.1007/s00277-017-3144.
    PubMed     Text format     Abstract available


  107. YANAGIHARA T, Ikematsu Y, Kato K, Yonekawa A, et al
    Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma.
    Ann Hematol. 2017 Oct 2. doi: 10.1007/s00277-017-3146.
    PubMed     Text format    


  108. SAMADI O, Breunis H, Sandoval J, Akilan K, et al
    Return to work and work-related disability among AML survivors.
    Ann Hematol. 2017;96:1625-1633.
    PubMed     Text format     Abstract available


  109. HANSSON L, Asklid A, Diels J, Eketorp-Sylvan S, et al
    Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.
    Ann Hematol. 2017;96:1681-1691.
    PubMed     Text format     Abstract available


  110. HAMADOU WS, Mani R, Besbes S, Bourdon V, et al
    GATA2 gene analysis in several forms of hematological malignancies including familial aggregations.
    Ann Hematol. 2017;96:1635-1639.
    PubMed     Text format     Abstract available


    September 2017
  111. HOU J, Wang S, Zhang Y, Fan D, et al
    Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
    Ann Hematol. 2017 Sep 22. doi: 10.1007/s00277-017-3130.
    PubMed     Text format     Abstract available


  112. JAWHAR M, Naumann N, Schwaab J, Baurmann H, et al
    Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
    Ann Hematol. 2017;96:1463-1470.
    PubMed     Text format     Abstract available


  113. HAROUN F, Solola SA, Nassereddine S, Tabbara I, et al
    PD-1 signaling and inhibition in AML and MDS.
    Ann Hematol. 2017;96:1441-1448.
    PubMed     Text format     Abstract available


    August 2017
  114. SHAO H, Yang Q, Wu C, Cen J, et al
    Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21).
    Ann Hematol. 2017 Aug 24. doi: 10.1007/s00277-017-3110.
    PubMed     Text format    


  115. OH SB, Park SW, Chung JS, Lee WS, et al
    Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
    Ann Hematol. 2017 Aug 21. doi: 10.1007/s00277-017-3104.
    PubMed     Text format     Abstract available


  116. IURLO A, Bucelli C, Cattaneo D, Orofino N, et al
    Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia.
    Ann Hematol. 2017 Aug 19. doi: 10.1007/s00277-017-3105.
    PubMed     Text format    


  117. LOU Y, Ma Y, Sun J, Suo S, et al
    Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia.
    Ann Hematol. 2017 Aug 19. doi: 10.1007/s00277-017-3096.
    PubMed     Text format     Abstract available


  118. ZHAO Y, Wang J, Luo Y, Shi J, et al
    Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
    Ann Hematol. 2017;96:1353-1360.
    PubMed     Text format     Abstract available


  119. SAGLIO G, le Coutre P, Cortes J, Mayer J, et al
    Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
    Ann Hematol. 2017;96:1303-1313.
    PubMed     Text format     Abstract available


  120. EREN R, Dogu MH, Emir S, Huq GE, et al
    Rethinking the usefulness of bone marrow biopsy on treatment decision in CLL patients at diagnosis.
    Ann Hematol. 2017;96:1315-1321.
    PubMed     Text format     Abstract available


    July 2017
  121. YUI S, Kurosawa S, Yamaguchi H, Kanamori H, et al
    D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
    Ann Hematol. 2017 Jul 31. doi: 10.1007/s00277-017-3074.
    PubMed     Text format     Abstract available


  122. NISCOLA P, Tendas A, Abruzzese E, Caravita T, et al
    Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice.
    Ann Hematol. 2017 Jul 12. doi: 10.1007/s00277-017-3064.
    PubMed     Text format    


  123. THOMAY K, Fedder C, Hofmann W, Kreipe H, et al
    Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions.
    Ann Hematol. 2017 Jul 9. doi: 10.1007/s00277-017-3055.
    PubMed     Text format     Abstract available


  124. VENTURA FERREIRA MS, Crysandt M, Ziegler P, Hummel S, et al
    Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia.
    Ann Hematol. 2017 Jul 3. doi: 10.1007/s00277-017-3049.
    PubMed     Text format     Abstract available


  125. RODRIGUEZ-VEIGA R, Igual B, Montesinos P, Tormo M, et al
    Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin.
    Ann Hematol. 2017;96:1077-1084.
    PubMed     Text format     Abstract available


  126. KAUR V, Swami A
    Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
    Ann Hematol. 2017;96:1175-1184.
    PubMed     Text format     Abstract available


    June 2017
  127. URESHINO H, Kamachi K, Miyahara M
    Detection of human T-cell lymphotropic virus type I-specific cytotoxic T-cells may predict treatment responses in adult T-cell leukemia/lymphoma patients.
    Ann Hematol. 2017 Jun 27. doi: 10.1007/s00277-017-3052.
    PubMed     Text format    


  128. BALDUCCI E, Nivaggioni V, Boudjarane J, Bouriche L, et al
    Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy.
    Ann Hematol. 2017 Jun 20. doi: 10.1007/s00277-017-3050.
    PubMed     Text format    


  129. HEUSER M, Gabdoulline R, Loffeld P, Dobbernack V, et al
    Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2017 Jun 13. doi: 10.1007/s00277-017-3027.
    PubMed     Text format     Abstract available


  130. JONSSON S, Olsson B, Soderberg J, Wadenvik H, et al
    Erratum to: Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study.
    Ann Hematol. 2017 Jun 9. doi: 10.1007/s00277-017-3024.
    PubMed     Text format    


  131. DE LACERDA MP, Guedes NR, Yamakawa PE, Pereira AD, et al
    Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with (del17p).
    Ann Hematol. 2017 Jun 9. doi: 10.1007/s00277-017-3039.
    PubMed     Text format    


  132. ABLA O, Ribeiro RC, Testi AM, Montesinos P, et al
    Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Ann Hematol. 2017 Jun 8. doi: 10.1007/s00277-017-3042.
    PubMed     Text format     Abstract available


  133. MUKHERJEE S, Ibrahimi S, John S, Adnan MM, et al
    Non-seminomatous mediastinal germ cell tumor and acute megakaryoblastic leukemia.
    Ann Hematol. 2017 Jun 3. doi: 10.1007/s00277-017-3037.
    PubMed     Text format     Abstract available


  134. OKA S, Ono K, Nohgawa M
    Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.
    Ann Hematol. 2017 Jun 2. doi: 10.1007/s00277-017-3032.
    PubMed     Text format    


  135. BRAULKE F, Schulz X, Germing U, Schuler E, et al
    Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
    Ann Hematol. 2017;96:887-894.
    PubMed     Text format     Abstract available


  136. CHOI DC, Tremblay D, Iancu-Rubin C, Mascarenhas J, et al
    Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.
    Ann Hematol. 2017;96:919-927.
    PubMed     Text format     Abstract available


    May 2017
  137. GONG Z, Zheng L, Tang Z, Chen Z, et al
    Erratum to: Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Ann Hematol. 2017 May 20. doi: 10.1007/s00277-017-3025.
    PubMed     Text format    


  138. HAEN SP, Groh C, Schumm M, Backert L, et al
    Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.
    Ann Hematol. 2017;96:817-827.
    PubMed     Text format     Abstract available


    April 2017
  139. MATERN S, Schmidt E, Hartmann D, Schliemann C, et al
    Successful second allogeneic stem cell transplantation in a patient with T-lymphoblastic leukemia (T-ALL) relapsed as myeloid sarcoma.
    Ann Hematol. 2017 Apr 27. doi: 10.1007/s00277-017-3000.
    PubMed     Text format    


  140. SANCHEZ R, Ayala R, Alonso RA, Martinez MP, et al
    Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.
    Ann Hematol. 2017 Apr 27. doi: 10.1007/s00277-017-3002.
    PubMed     Text format     Abstract available


  141. KOYA J, Ibaraki T, Yamazaki I, Nakamura F, et al
    Acute basophilic leukemia with add(3)(q12) accompanied by histamine excess symptoms.
    Ann Hematol. 2017 Apr 19. doi: 10.1007/s00277-017-2987.
    PubMed     Text format    


  142. ESPINOSA LARA P, Quiros Redondo V, Aguado Lobo M, Jimenez-Reyes J, et al
    Purpuric exanthema in a patient with hairy cell leukemia treated with cladribine and allopurinol.
    Ann Hematol. 2017 Apr 8. doi: 10.1007/s00277-017-2992.
    PubMed     Text format    


  143. SHUSTIK C, Bence-Bruckler I, Delage R, Owen CJ, et al
    Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
    Ann Hematol. 2017 Apr 7. doi: 10.1007/s00277-017-2982.
    PubMed     Text format     Abstract available


    March 2017
  144. DUNOYER-GEINDRE S, Rivier-Cordey AS, Tsopra O, Lecompte T, et al
    Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1beta.
    Ann Hematol. 2017 Mar 25. doi: 10.1007/s00277-017-2970.
    PubMed     Text format     Abstract available


  145. BOTH A, Krauter J, Damm F, Thol F, et al
    The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.
    Ann Hematol. 2017 Mar 22. doi: 10.1007/s00277-017-2967.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: